Last reviewed · How we verify
Insulin/Canaglifozin
This combination product delivers insulin for glycemic control while canagliflozin inhibits SGLT2 to increase urinary glucose excretion, providing complementary glucose-lowering effects.
This combination product delivers insulin for glycemic control while canagliflozin inhibits SGLT2 to increase urinary glucose excretion, providing complementary glucose-lowering effects. Used for Type 2 diabetes mellitus.
At a glance
| Generic name | Insulin/Canaglifozin |
|---|---|
| Sponsor | University of Campania Luigi Vanvitelli |
| Drug class | Insulin + SGLT2 inhibitor combination |
| Target | Insulin receptor; SGLT2 (sodium-glucose cotransporter 2) |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | FDA-approved |
Mechanism of action
Insulin acts as a replacement hormone to facilitate glucose uptake and utilization in peripheral tissues. Canagliflozin, an SGLT2 inhibitor, blocks reabsorption of filtered glucose in the proximal tubule, promoting urinary glucose excretion. Together, they address hyperglycemia through distinct mechanisms: insulin-mediated glucose utilization and SGLT2-mediated renal glucose loss.
Approved indications
- Type 2 diabetes mellitus
Common side effects
- Hypoglycemia
- Genital mycotic infections
- Urinary tract infections
- Diabetic ketoacidosis
- Volume depletion
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Insulin/Canaglifozin CI brief — competitive landscape report
- Insulin/Canaglifozin updates RSS · CI watch RSS
- University of Campania Luigi Vanvitelli portfolio CI